Shanghai Kehua Bio-Engineering Co., Ltd. operates within the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shanghai Kehua Bio-Engineering Co., Ltd. with three other
companies in this sector in China:
MedicalSystem Biotechnology Co Ltd
sales of 1.81 billion Chinese Renmimbi [US$261.62 million]
of which 72%
was In vitro diagnostic reagent),
DA AN Gene Co.,Ltd. Of Sun Yat-Sen University
(1.54 billion Chinese Renmimbi [US$223.53 million]
of which 95%
was Biological Products), and
Maccura Biotechnology Co Ltd
(1.97 billion Chinese Renmimbi [US$285.51 million]
of which 50%
was Agent reagent).
During the year ended December of 2017, sales at
Shanghai Kehua Bio-Engineering Co., Ltd. were 1.59 billion Chinese Renmimbi (US$231.04 million).
increase of 14.1%
versus 2016, when the company's sales were 1.40 billion Chinese Renmimbi.